News stories about Calithera Biosciences (NASDAQ:CALA) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.1315455500608 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Sell-Side Research on Modine Manufacturing Company (MOD), Calithera Biosciences, Inc. (CALA) – StockNewsMagazine (stocknewsmagazine.com)
- Should You Buy Paratek Pharmaceuticals, Inc. (PRTK) or Calithera Biosciences, Inc. (CALA)? – StockNewsGazette (stocknewsgazette.com)
- Q3 2017 EPS Estimates for Calithera Biosciences, Inc. (NASDAQ:CALA) Cut by Leerink Swann (americanbankingnews.com)
- Calithera Biosciences, Inc. (NASDAQ:CALA) Technical Analysis Indicators – StockNewsGazette (stocknewsgazette.com)
- Calithera Biosciences Inc : Investor Network: Calithera Biosciences, Inc. to Host Earnings Call (4-traders.com)
Several equities research analysts have recently weighed in on the stock. BidaskClub cut shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target (up previously from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $20.00 price target (up previously from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. Finally, Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, May 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $15.50.
Shares of Calithera Biosciences (CALA) traded up 15.35% on Friday, reaching $13.90. 1,034,907 shares of the company’s stock were exchanged. Calithera Biosciences has a one year low of $2.20 and a one year high of $20.05. The firm has a 50 day moving average of $15.88 and a 200 day moving average of $12.74. The firm’s market capitalization is $493.12 million.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.14. The company had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities research analysts predict that Calithera Biosciences will post ($0.83) EPS for the current year.
In related news, VP Keith Orford sold 2,120 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $18.31, for a total value of $38,817.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 3,470 shares of company stock valued at $61,817 in the last quarter. 16.30% of the stock is currently owned by corporate insiders.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.